Lilly's $2.75B AI Drug Deal with Insilico; Oral Psoriasis Data Reshapes Derm at AAD 2026

Eli Lilly just put two point seven five billion dollars behind AI-discovered drugs, the largest generative biology deal this industry has seen.

And while everyone was watching that headline, AAD and ACC quietly delivered a week of clinical data that could redraw how we treat psoriasis, atopic dermatitis, and pulmonary embolism. Let's get into all of it.

Welcome to The Pharma Closeout Weekend Edition for Sunday, March twenty-ninth, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. It was a packed week. Let's take it apart.

The deal that landed this morning: Eli Lilly and Insilico Medicine, a drug discovery collaboration worth up to two point seven five billion dollars in total biobucks. Lilly pays one hundred fifteen million upfront for an exclusive worldwide license to a portfolio of AI-discovered oral therapeutics across multiple therapeutic areas, with metabolic diseases specifically named. Insilico, listed on the Hong Kong exchange since late twenty twenty-five, brings its generative AI engine. Lilly handles development, manufacturing, and global commercialization.

The structure is more interesting than the headline number. One hundred fifteen million upfront on a two point seven five billion total. That's roughly four percent committed today. The rest is development, regulatory, and commercial milestones plus tiered royalties. Lilly isn't buying a drug here. They're buying optionality on a platform, and they've priced the risk accordingly.

But the scale of that optionality is what makes this different from every other AI-pharma partnership we've tracked. Lilly is guiding eighty to eighty-three billion in twenty twenty-six revenue. They have the cash flow to absorb platform bets without blinking. And this isn't an experiment for them. They've been co-building an AI discovery lab with NVIDIA, investing in internal computational infrastructure. The Insilico deal layers an external generative biology engine on top of what they're already constructing in-house.

The therapeutic positioning is where I'd focus. The announcement specifically highlights oral therapeutics for metabolic diseases. Lilly generated over thirty-six billion combined from Mounjaro and Zepbound in twenty twenty-five. So what are they doing licensing AI-discovered oral metabolic candidates? They're not defending the GLP-1 franchise. They're building a second wall behind it for whatever comes next in the metabolic space.

Let's bring in Marcus Webb on the deal structure.

Here's the broader read. When the company with arguably the strongest balance sheet in pharma signs a deal at this total value with a generative biology platform, it sends a signal far beyond the two parties involved. Every smaller AI-drug discovery company trying to raise capital or find a partner just got their valuation floor reset.

Staying in the deal landscape, the action wasn't limited to AI. In Europe, Angelini Pharma and Recordati are in active merger negotiations. Recordati is controlled by CVC Capital Partners, which acquired fifty-one point eight percent in twenty eighteen for three billion euros. After a six percent share price rise in twenty twenty-four, Recordati's market value reached ten point eight billion euros, roughly eleven point four billion dollars.

The history here is revealing. In June twenty twenty-four, Angelini partnered with KKR, TPG, and Advent International to explore acquiring Recordati. They walked away over valuation and strategic disagreements. Now Angelini is back at the table, apparently without the PE consortium. Either the pricing expectations have moved, or the strategic logic of merging their CNS and epilepsy portfolio with Recordati's cardiovascular and urology franchise has become compelling enough to pursue alone.

Let's bring Marcus Webb back for the structural picture.

For US-focused listeners, here's why this matters. If this deal closes, it creates one of Europe's largest specialty pharma players with the scale to compete more aggressively on global licensing for late-stage specialty assets. That kind of consolidated buying power on the other side of the Atlantic changes the competitive dynamics for anyone trying to out-license a specialty program.

This was one of those rare weeks where two major medical meetings ran simultaneously and both delivered. AAD in Denver. ACC in New Orleans. The clinical data volume was extraordinary, so let me triage what actually reshapes competitive dynamics.

Start with derm. That's where the biggest surprises landed.

The story is the oral psoriasis race, and it's no longer theoretical. Johnson and Johnson presented fifty-two-week Phase 3 data for ICOTYDE, their oral peptide blocking the IL-23 receptor. In the ICONIC-ADVANCE studies, PASI 100 complete clearance rates climbed from forty-one and thirty-three percent at Week 24 to forty-nine and forty-eight percent at Week 52. Patients who crossed over from placebo caught up by Week 52. And here's the competitive nuance: adverse event and infection rates came in lower than deucravacitinib through Week 24.

And Takeda showed up with its own entry in the same late-breaking session.

Zasocitinib. Their highly selective TYK2 inhibitor. The LATITUDE studies showed seventy-one and sixty-nine percent of patients achieving clear or almost clear skin at Week 16. PASI 90 rates hit sixty-one and fifty-two percent, both dramatically above apremilast comparator arms running in the low thirties. And they demonstrated significant PASI 75 separation as early as Week 4. That speed of onset in an oral agent is notable.

So now you have two credible oral mechanisms delivering data that genuinely challenges injectable benchmarks in psoriasis.

That's the takeaway from Denver on psoriasis. But derm didn't stop there. Sanofi dropped Phase 3 data on amlitelimab in atopic dermatitis across three studies: COAST 1, COAST 2, and SHORE. Amlitelimab targets OX40-ligand, a completely different pathway than Dupixent's IL-4/13 blockade. Both Q4W and Q12W dosing arms showed progressively increasing efficacy with no plateau at Week 24. The Q12W data from the start of treatment is what matters strategically. A biologic dosed four times a year in a space where the current standard is biweekly or daily. That's not an incremental improvement. And the OX40L mechanism opens the door for the patients who aren't fully controlled on existing options, which expands the addressable population rather than simply cannibalizing Dupixent.

MoonLake also presented in HS.

Sonelokimab Week 40 data from the Phase 3 VELA-1 and VELA-2 trials. Sixty-two percent of patients on HiSCR75, up to thirty-two percent on HiSCR100, and twenty-five percent achieving inflammatory remission defined as simultaneous one hundred percent clearance of abscesses, nodules, and draining tunnels. Using HiSCR75 as a primary endpoint is itself a higher bar than the HiSCR50 standard from earlier HS registration programs. A quarter of patients reaching full inflammatory remission at Week 40 in a disease this refractory is a signal that deserves attention beyond the derm community.

Now, across the country at ACC in New Orleans, Boston Scientific had its own landmark moment.

The HI-PEITHO trial. Five hundred forty-four patients with intermediate-risk PE across fifty-nine sites. Ultrasound-facilitated catheter-directed thrombolysis with the EKOS system versus anticoagulation alone. At thirty days, the primary composite, PE-related death, cardiorespiratory decompensation, or symptomatic recurrence, hit four percent in the catheter arm versus ten point three percent in the control arm. Sixty-one percent relative reduction, driven by fewer decompensation events. No intracranial hemorrhage in either group. No significant difference in major bleeding. And critically, per the investigators, this is the first randomized trial to directly compare clinical outcomes between a catheter-based strategy and systemic anticoagulation alone in this population. Results simultaneously published in the New England Journal.

That doesn't just support EKOS adoption. It gives interventional teams and hospital systems the evidence they've been waiting for to justify building out PE response programs with catheter-based capability. The practice-level implications here are immediate.

Under the radar this week, genuinely buried by the derm and deal avalanche: Merck presented Phase 2 CADENCE data for WINREVAIR in a completely new patient population. Not the pulmonary arterial hypertension indication where sotatercept already has an approval. This is combined post- and precapillary pulmonary hypertension with heart failure with preserved ejection fraction. CpcPH-HFpEF.

A population with no approved treatment options. What did the data look like?

WINREVAIR met its primary endpoint. A one point zero two Wood units reduction in pulmonary vascular resistance at the zero point three milligram per kilogram dose versus placebo at Week 24. Statistically significant. The investigators described it as clinically meaningful in a population with high morbidity, high mortality, and an aging comorbid profile. Merck is moving directly into a registrational Phase 3.

This could be one of the most consequential lifecycle stories of twenty twenty-six for a drug that's already on the market. CpcPH-HFpEF patients are older, sicker, and more numerous than the classic PAH population. A second indication in a distinct hemodynamic phenotype could rival the existing franchise over time. And the fact that Merck's proof-of-concept data was strong enough to bypass additional Phase 2 work and go straight to pivotal tells you they see exactly the same commercial runway.

Looking at the week ahead, two PDUFA dates stand out. First, Orca Bio's Orca-T on April sixth, the allogeneic T-cell immunotherapy for hematologic malignancies.

The PRECISION-T data supporting that application showed seventy-eight percent one-year survival free of moderate-to-severe chronic graft-versus-host disease versus thirty-eight percent with standard transplant. A positive decision would meaningfully change how transplant centers stratify graft-versus-host risk.

Then, April tenth. Lilly's orforglipron. The FDA extended the review period, so the PDUFA now falls on the tenth. That decision will set the competitive tone for the entire oral incretin landscape for the next two years.

And AAD wraps up tomorrow in Denver, so watch for any final late-breaking presentations filtering through.

The Q2 calendar is stacking up fast. Multiple PDUFA dates in the first two weeks of April alone.

Which brings this week full circle. The oral psoriasis data from Denver plus the pending orforglipron decision creates a single clear narrative heading into Q2: the industry's push toward oral alternatives to injectables is about to face its biggest regulatory test. How the FDA evaluates that first wave will shape development strategy across therapeutic areas for years to come.

That wraps our Weekend Closeout. Lilly's two point seven five billion dollar AI bet with Insilico. Angelini and Recordati circling a European mega-merger. ICOTYDE and zasocitinib rewriting oral psoriasis. Boston Scientific's HI-PEITHO landing in the New England Journal. And Merck quietly positioning WINREVAIR for a second life in heart failure. This industry packs more into one week than most sectors see in a quarter, and honestly, we love covering it. If this briefing keeps you sharp, follow us on Spotify, drop a rating, and tell a colleague who needs to hear it. We're back tomorrow.

Enjoy your Sunday evening. See you tomorrow.